Boston Scientific Interventional Oncology & Embolization revenue
Interventional Oncology & Embolization revenue at Boston Scientific came to $267.0M for the quarter to 30 Sep 2026, up 5.5% from a year earlier.
As Boston Scientific reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 2 Nov 2026.
By quarter
| Period ending | Interventional Oncology & Embolization revenue | Change on a year | Filed |
|---|---|---|---|
| 30 Sep 2026 | $267.0M | up 5.5% | 2 Nov 2026 |
| 30 Jun 2026 | $283.0M | up 12.7% | 3 Aug 2026 |
| 31 Mar 2026 | $268.0M | up 17.5% | 1 May 2026 |
| 31 Dec 2025 | $263.0M | — | 17 Feb 2026 |
| 30 Sep 2025 | $253.0M | — | 3 Nov 2025 |
| 30 Jun 2025 | $251.0M | — | 1 Aug 2025 |
| 31 Mar 2025 | $228.0M | — | 1 May 2025 |
Definition
Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.
Other operating KPIs of Boston Scientific: Interventional Cardiology & Vascular Therapies revenue · Electrophysiology revenue · Endoscopy revenue · Peripheral Interventions revenue · Urology revenue · Cardiac Rhythm Management revenue · Watchman revenue · Neuromodulation revenue · Cardiology revenue · Cardiovascular revenue · MedSurg revenue · United States revenue · Int'l revenue · Emerging Markets revenue · financial statements
Every KPI and segment of BSX, in the terminal.
Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.
